coronaviru
diseas
initi
viralrepl
phase
often
follow
hyperinflammatori
reaction
lung
organ
system
lead
acut
respiratori
distress
syndrom
ard
need
mechan
ventil
death
despit
maxim
support
care
antivir
treatment
yet
proven
effect
effort
prevent
progress
sever
stage
without
inhibit
antivir
immun
respons
desper
need
previous
demonstr
common
inexpens
welltoler
class
drug
call
adrenerg
receptor
antagonist
prevent
hyperinflamm
cytokin
storm
death
mice
present
clinic
data
support
use
antagonist
prevent
sever
complic
pneumonia
ard
emerg
evid
suggest
subset
character
develop
cytokin
storm
syndrom
css
resembl
cytokin
releas
syndrom
cr
chimer
antigen
receptor
car
cell
therapi
hyperinflamm
associ
elev
proinflammatori
cytokin
includ
interleukin
il
tumor
necrosi
granulocytecoloni
stimul
factor
similar
exuber
cytokin
product
lunginfiltr
monocytesmacrophag
pneumocyt
observ
merscov
infect
alveolar
inflamm
diffus
alveolar
damag
impair
infect
lung
local
abil
particip
ga
exchang
culmin
ard
necessit
mechan
ventil
ard
main
driver
mortal
thu
prevent
hyperinflamm
critic
avoid
progress
one
potenti
target
signal
pathway
level
diverg
profoundli
survivor
nonsurvivor
third
week
symptom
onset
predictor
sever
inhospit
mortal
tocilizumab
monoclon
antibodi
target
receptor
current
investig
treatment
patient
pend
data
random
control
trial
retrospect
data
patient
sever
critic
treat
tocilizumab
suggest
inhibit
signal
axi
highli
effect
howev
given
cost
immunosuppress
potenti
advers
reaction
tocilizumab
strategi
like
restrict
select
patient
develop
countri
recent
shown
cr
observ
bacteri
infect
cart
cell
cellactiv
therapi
accompani
surg
catecholamin
catecholamin
enhanc
inflammatori
injuri
augment
product
cytokin
selfamplifi
feedforward
loop
immun
cell
requir
adrenerg
receptor
signal
prophylact
inhibit
catecholamin
synthesi
metyrosin
tyrosin
hydroxylas
antagonist
reduc
level
catecholamin
cytokin
respons
result
markedli
increas
surviv
follow
variou
inflammatori
stimuli
mice
similar
protect
hyperinflammatori
stimulu
observ
welltoler
antagonist
prazosin
betaadrenerg
receptor
antagonist
demonstr
class
drug
also
prevent
cytokin
storm
date
control
trial
examin
potenti
benefit
antagon
prevent
css
mitig
ard
human
subject
investig
role
antagonist
prevent
poor
outcom
result
pulmonari
hyperinflammatori
respons
conduct
retrospect
analysi
two
cohort
yearold
hospit
patient
marketscan
research
databas
databas
patient
would
expect
take
antagonist
treatment
chronic
condit
unrel
ard
benign
prostat
hyperplasia
hypertens
due
difficulti
determin
claim
data
whether
individu
take
prescrib
medic
given
time
defin
prior
use
patient
fill
antagonist
prescript
doxazosin
prazosin
silodosin
terazosin
tamsulosin
year
preced
event
aggreg
day
logist
regress
model
use
estim
odd
ratio
adjust
odd
ratio
aor
confid
interv
ci
correl
receipt
antagonist
two
separ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
outcom
measur
progress
requir
invas
mechan
ventil
hospit
b
progress
death
ventil
model
adjust
comorbid
hypertens
ischem
heart
diseas
acut
myocardi
infarct
heart
failur
chronic
obstruct
pulmonari
diseas
diabet
mellitu
posttraumat
stress
disord
identifi
health
care
encount
prior
year
well
age
year
first
cohort
consist
patient
identifi
intern
classif
diseas
icd
code
encompass
acut
respiratori
failur
includ
ard
men
cohort
found
patient
prior
use
antagonist
overal
patient
receiv
invas
mechan
ventil
ventil
die
hospit
found
patient
prior
use
antagonist
lower
incid
invas
mechan
ventil
compar
nonus
ci
ci
figur
b
c
perhap
importantli
patient
lower
incid
ventil
die
hospit
ci
ci
figur
b
contrast
prior
use
betaadrenerg
receptor
antagonist
correl
either
outcom
cohort
figur
c
second
cohort
consist
patient
admit
pneumonia
identifi
agenc
healthcar
research
qualiti
ahrq
pneumonia
categori
compris
number
code
respect
subject
cohort
patient
take
antagonist
overal
patient
receiv
invas
mechan
ventil
ventil
die
hospit
found
patient
prior
use
antagonist
lower
incid
invas
mechan
ventil
compar
nonus
ci
ci
p
figur
e
f
patient
lower
incid
ventil
die
hospit
ci
ci
figur
e
g
contrast
prior
use
antagonist
correl
either
outcom
cohort
without
adjust
figur
f
g
state
result
robust
multipl
propens
weight
approach
includ
causal
forest
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
variant
find
suggest
antagonist
may
protect
immunemedi
morbid
mortal
result
common
lung
injuri
infect
taken
togeth
result
extend
preclin
find
support
clinic
rational
studi
antagonist
prophylaxi
sever
state
local
system
immun
dysregul
prazosin
inexpens
safe
document
longterm
treatment
million
patient
benign
prostat
hyperplasia
hypertens
condit
howev
drug
unanticip
side
effect
differ
clinic
context
incomplet
understood
relationship
hypertens
suggest
caution
use
agent
impact
blood
pressur
given
limit
retrospect
studi
one
prospect
clinic
trial
antagonist
highrisk
patient
therefor
requir
assess
util
prevent
emphas
extens
experi
use
prazosin
indic
priorit
obviat
rigor
control
clinic
research
rather
indiscrimin
offlabel
use
patient
expos
infect
trial
could
expediti
implement
area
suffer
high
infect
rate
overwhelm
hospit
capac
end
activ
pursu
clinic
trial
multipl
institut
make
protocol
avail
http
clinicaltrialsgov
approv
john
hopkin
intern
review
board
encourag
reader
contact
us
andor
launch
trial
base
compel
retrospect
analys
coupl
pathophysiolog
mechanist
explan
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
analyz
health
care
claim
data
dr
sacarni
compens
assist
studi
use
ibm
marketscan
research
databas
research
includ
data
analysi
partial
support
fund
microsoft
research
disclosur
john
hopkin
univers
jhu
file
patent
applic
use
variou
drug
prevent
cytokin
releas
syndrom
vs
rb
np
bv
kwk
sz
list
inventor
jhu
assert
patent
right
file
treatment
relat
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
